Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mei Pharma Inc (MEIP)

Mei Pharma Inc (MEIP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 100,813
  • Shares Outstanding, K 32,838
  • Annual Sales, $ 65,300 K
  • Annual Income, $ 17,780 K
  • EBIT $ -27 M
  • EBITDA $ -15 M
  • 60-Month Beta 0.38
  • Price/Sales N/A
  • Price/Cash Flow 0.51
  • Price/Book 1.05
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.20
  • Most Recent Earnings $-0.39 on 05/13/25
  • Next Earnings Date 09/18/25
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -1.13
  • Growth Rate Est. (year over year) +88,507.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.76 +11.23%
on 09/09/25
5.55 -44.66%
on 08/11/25
-2.12 (-40.85%)
since 08/08/25
3-Month
2.20 +39.55%
on 06/24/25
9.00 -65.89%
on 07/18/25
+0.77 (+33.48%)
since 06/10/25
52-Week
1.46 +110.27%
on 04/16/25
9.00 -65.89%
on 07/18/25
-0.03 (-0.84%)
since 09/10/24

Most Recent Stories

More News
MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS’

Lite Strategy Rebrand Aligns with Company’s LTC Digital Asset Treasury Strategy Advised by GSR Ventures

MEIP : 3.07 (+10.43%)
LITS : 1.6700 (-4.57%)
MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising

MEI Pharma, Inc. (NASDAQ: MEIP) (“MEI” or “the Company”) today announced the acquisition of 929,548 Litecoin (LTC) tokens at an average price of $107.58, successfully launching a major institutional...

MEIP : 3.07 (+10.43%)
MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange

Charlie Lee, the Founder of Litecoin and a lead investor in the PIPE, has joined the Board of Directors of the Company ...

MEIP : 3.07 (+10.43%)
MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange

Charlie Lee, the Founder of Litecoin and a lead investor in the PIPE, will join the Board of Directors of the Company effective upon the closing of the...

MEIP : 3.07 (+10.43%)
MEI Pharma Announces 1-for-20 Reverse Stock Split

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that its board of directors approved a 1-for-20 reverse stock split....

MEIP : 3.07 (+10.43%)
SHAREHOLDER ALERT: Weiss Law Investigates Infinity Pharmaceuticals, Inc.

/PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Infinity...

INFI : 0.0080 (-50.00%)
MEIP : 3.07 (+10.43%)
INFINITY PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Infinity Pharmaceuticals, Inc. - INFI

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Infinity Pharmaceuticals, Inc. (the “Company”)...

INFI : 0.0080 (-50.00%)
MEIP : 3.07 (+10.43%)
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Infinity Pharmaceuticals, Inc.

/PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and its board of...

INFI : 0.0080 (-50.00%)
MEIP : 3.07 (+10.43%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNKB, PTRS, JNCE, MEIP

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

PTRS : 7.15 (+0.99%)
JNCE : 1.8800 (-2.59%)
LNKB : 7.72 (-0.64%)
MEIP : 3.07 (+10.43%)
MEIP STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of MEI Pharma, Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of MEI Pharma, Inc. (NASDAQ: MEIP) and Infinity Pharmaceuticals, Inc. is fair to MEI shareholders. Per the merger agreement,...

MEIP : 3.07 (+10.43%)

Business Summary

MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards,...

See More

Key Turning Points

3rd Resistance Point 3.66
2nd Resistance Point 3.46
1st Resistance Point 3.26
Last Price 3.07
1st Support Level 2.86
2nd Support Level 2.66
3rd Support Level 2.46

See More

52-Week High 9.00
Fibonacci 61.8% 6.12
Fibonacci 50% 5.23
Fibonacci 38.2% 4.34
Last Price 3.07
52-Week Low 1.46

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar